Francesca De Felice1, Claudia Marchetti2, Vincenzo Tombolini3, P Benedetti Panici4. 1. Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy. fradefelice@hotmail.it. 2. Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy. 3. Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy. 4. Department of Gynecological, Obstetrical Sciences and Urological Sciences "Sapienza" University of Rome, Rome, Italy.
Abstract
BACKGROUND: Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors. METHODS: Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles. RESULTS: Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status. CONCLUSIONS: Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.
BACKGROUND:Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors. METHODS: Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles. RESULTS: Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status. CONCLUSIONS: Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.
Authors: Charles R Wira; John V Fahey; Mimi Ghosh; Mickey V Patel; Danica K Hickey; Daniel O Ochiel Journal: Am J Reprod Immunol Date: 2010-03-29 Impact factor: 3.886
Authors: Kimberly E Resnick; Wendy L Frankel; Carl D Morrison; Jeffrey M Fowler; Larry J Copeland; Julie Stephens; Kenneth H Kim; David E Cohn Journal: Gynecol Oncol Date: 2010-02-13 Impact factor: 5.482
Authors: Karuna Garg; Karin Shih; Richard Barakat; Qin Zhou; Alexia Iasonos; Robert A Soslow Journal: Am J Surg Pathol Date: 2009-12 Impact factor: 6.394
Authors: Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine Journal: Nature Date: 2013-05-02 Impact factor: 49.962